Hebrew University of Jerusalem launched 15 spinouts last year covering areas ranging from healthcare to solar energy.
Yissum, the technology transfer arm of Hebrew University of Jerusalem, launched a total of 15 spinouts last year.
The companies are:
- RNAWay, which has developed a platform for delivering siRNA to plants;
- Immunyx Pharma, which is working on technology for neutrophil specific targeting a mode of immunotherapy;
- Lipovac, which has set its sights on a liposome-based vaccine to treat conditions including covid;
- ExoNavis Therapeutics, which is focusing on exosome-based drug delivery;
- NexoCarp, which is pickering solid dispersion and particles for the delivery of agents;
- PSYRX, a tissue culture protocols developer targeting central nervous system diseases;
- MyComed Super Foods, which plans to use medicinal herbs and spirulina algae to prevent osteoporosis;
- Cavos, which is exploiting artificial intelligence and machine learning to create diagnostic, prognostic and treatment options for a range of diseases;
- Noga3D, which will market 3D-printing materials based on epoxies;
- I-Red Pharma, which will commercialise a treatment for conditions with new small and multi-property molecules;
- Solra, which plans to sellfully screen-printable perovskite solar cells;
- Sea2Cell, which is working on cultured fish;
- EverBlue Labs, which will marketzero-discharge fish aquariums;
- Bountica, which has createdanti-fungal peptides; and
- RNable, which has identified a novel target for the treatment of rare genetic diseases and cancer caused by nonsense mutations.
Itzik Goldwaser, chief executive of Yissum, said: “Yissum has long been considered Israel’s leading technology transfer company, but our recent successes along with the unprecedented level of portfolio companies, investment partners, and highly promising early-stage tech serve as a real-life testament to that fact.
“While this group of startups shows promise when it comes to commercial success, they are also poised to change millions of lives and we will continue to help foster and scale these technologies in order to achieve their full potential.”
